

Haematologica
HAEMATOL/2018/209924
Version 3

Extended anticoagulant therapy in venous thromboembolism: a balanced, fractional factorial, clinical vignette-based study

Vincent ten Cate, Anthonie WA Lensing, Jeffrey I Weitz, Jan Beyer-Westendorf, Philip S Wells, Patrick Mismetti, Paolo Prandoni, Alexander T Cohen, Bruce L Davidson, and Martin H Prins

Disclosures: This work was supported by an unrestricted grant from Bayer AG. VTC declares no competing interests. AWAL is an employee of Bayer. JIW has received personal fees from Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Pfizer, Daiichi-Sankyo, and Servier. JB-W has received personal fees from Bayer, Boehringer Ingelheim, Pfizer, Daiichi-Sankyo, Portola. PSW has received research funding from BMS/Pfizer and has received personal fees from Bayer, and Janssen Scientific Affairs. PM has received personal fees from Bayer, Boehringer Ingelheim, BMS/Pfizer, Daiichi-Sankyo, and Leo Pharma. PP has received personal fees from Bayer AG, Sanofi, Daiichi-Sankyo, and Pfizer. ATC has received personal fees from AbbVie, Aspen, Bayer, Boehringer-Ingelheim, Bristol-Myers Squibb, Daiichi-Sankyo, Janssen, Leo Pharma, Ono Pharmaceuticals, Pfizer, and Portola. BLD has received personal fees from Portola, Bayer, and Johnson and Johnson. MHP has received personal fees from Bayer, Daiichi-Sankyo and Pfizer.

Contributions: VTC and MHP conceived of and designed the study. VTC implemented the experimental design and carried out the statistical analysis. VTC, AWAL, JIW, JB-W, PSW, PM, PP, ATC, BLD and MHP interpreted the results and wrote the manuscript.